Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND
BCAX•Bicara Therapeutics posted a Q1 net loss of $8.3 million, R&D spending of $5.1 million and SG&A expenses of $3.2 million, leaving $62.5 million in cash at March 31. The company advanced BT-11 into Phase 1b/2a atopic dermatitis trials and filed an IND for BT-12 psoriasis.
1. Q1 Financial Results
Bicara reported a Q1 2026 net loss of $8.3 million, driven by R&D expenses of $5.1 million and SG&A costs of $3.2 million as it invests in its dermatology pipeline.
2. Pipeline Progress
The company advanced its lead candidate BT-11 into Phase 1b/2a trials for atopic dermatitis, completing initial enrollment, and submitted an IND for BT-12 targeting psoriasis to begin clinical evaluation.
3. Cash Position and Runway
With $62.5 million in cash and equivalents as of March 31, Bicara projects funding is sufficient to support operations and pipeline development into late 2027.
